• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

    1/9/24 8:44:00 AM ET
    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNLI alert in real time by email

    Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022

    Company Closes Financing Round at Nearly $270 Million

    Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors 

    CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Bekhouche (Investment Corporation of Dubai) and Noubar Afeyan (Flagship Pioneering) to its Board of Directors. As a follow up to the company's initial financing announcement in September 2023, Indigo also announced the final close of its financing round at an expanded raise of nearly $270 million.

    Indigo Ag Logo

    Banks is the former President and CEO of Tyson Foods and a former member of the leadership team at X (an Alphabet company, formerly known as Google [X]), in addition to holding numerous leadership and entrepreneurial roles across the food, agriculture, technology and life sciences industries. He succeeds Ron Hovsepian, who has served as the company's Chief Executive Officer since September 2020. During his tenure, Hovsepian was responsible for successfully producing the world's first crop of registry-issued ag carbon credits at scale, expanding the company's industry-leading biological seed treatments, and the ongoing development and deployment of second-generation digital merchandising solutions. 

    "On behalf of the Board of Directors, I would like to thank Ron for his leadership in taking Indigo to a new level of performance and growth and laying the foundation for its forward path in becoming the undisputed leader in the transformation to regenerative agriculture," said Robert Berendes, Ph.D., Chairman of the Board, Indigo Ag and Executive Partner, Flagship Pioneering. "We are delighted Ron will continue to contribute to Indigo's success as a board member and an advisor to the CEO."

    Berendes continued, "Dean has been a strategic and deeply engaged board member for Indigo, drawing on his extensive experience as an entrepreneur, technologist, innovator, and business executive. He is an energizing leader and visionary, and I am confident he will steward the company into this next critical phase of growth and profitability, and ultimately realize the full potential of the Indigo platform for companies, farmers, and the planet."

    "Dean brings entrepreneurial and operational experience and excellence to Indigo and an extensive track record in building value for life sciences, tech, and food companies, and he joins at an exciting time, given the recent close of the company's latest financing round," said Noubar Afeyan, Founder and CEO of Flagship Pioneering and Co-Founder of Indigo Ag. "His unique background makes him well-positioned to realize Indigo's bold ambitions and also to contribute to Flagship's growing sustainability portfolio."

    "I'm thrilled to take on the role of CEO of Indigo Ag. Over the last year on the board, I have witnessed the tremendous investment we've made to build scientifically validated digital sustainability tools and biological products that farmers, agribusiness, our CPG partners, and our planet urgently need," said Dean Banks, Incoming CEO of Indigo Ag and CEO-Partner of Flagship Pioneering. "Indigo's solutions are delivering on their promise to help make our farmers more successful today, driving higher yields and new revenue streams while helping them nurture their soil for better tomorrows. The company is uniquely positioned as a trusted, independent partner impacting millions of acres today across the agricultural value chain. I look forward to working with the team to take the company to the next level as we scale its growth and impact."

    About Dean Banks

    Banks most recently served as President and CEO of Tyson Foods where he was responsible for charting the long-term vision and transformation plan for the company including integration of advanced technologies like artificial intelligence, robotics, sustainable supply chain solutions and development of alternative proteins throughout its operations. During his four-year tenure with the company, he also served on the Board and executive leadership team.

    Banks joined Tyson from the high-tech incubator at Alphabet, the company formerly known as Google [X], where he served on the leadership team and led moonshot projects across multiple industries including sustainable food (as co-founder of Tidal) and robotics (as co-founder of Intrinsic).

    Banks was previously managing partner of SEED Ventures, a group investing in and developing early-stage healthcare technologies. He also has served as a consultant to Cleveland Clinic Innovations, SVP of Business Development and Strategic Marketing at OrthoHelix, co‐founder and CEO of Connective Orthopedics, and Vice President at Highland Capital Partners. He currently serves on the Boards of Vergent Bioscience (where he was a co-founder and founding CEO), on the Advisory Board of Shiru, and is a Sr. Advisor at Advent International.

    Banks served as a former platoon sergeant and squad leader in the U.S. Marine Corps. He holds a Bachelor of Arts from Miami University and a Master of Business Administration from the Harvard Business School.

    Company Closes Financing Round

    Indigo recently closed a financing round at nearly $270 million. As announced in September 2023, Indigo's funding round included existing investors, led by Flagship Pioneering, and new investors, including the State of Michigan Retirement System, one of the largest pension funds in the U.S. and Lingotto Investment Management, a $3 billion innovation-focused fund owned by Exor N.V., one of Europe's largest diversified holding companies.

    "This latest funding round is a testament to the power of Indigo's platform and positions the company for growth across all aspects of the business, from biologicals to digital to carbon," said Berendes.

    Indigo Adds to Board of Directors

    As members of the board, Nader Bekhouche and Noubar Afeyan bring decades of experience to the company's leadership team and will help Indigo Ag take the next step to deliver meaningful and impactful solutions that turn sustainable practices into value for its farmer, agribusiness, and corporate customers.

    Berendes noted, "I'm thrilled to add these two uniquely skilled leaders to our board. Their addition will further strengthen our board and its ability to quickly and decisively make important decisions that will benefit our farming community, our corporate customers, and the planet."

    Nader Bekhouche is currently heading the Growth Equity investment team at Investment Corporation of Dubai, the principal investment arm of the Government of Dubai, which he joined in 2015. Bekhouche has held many positions in the technology, agriculture and food industries. For the past, four years, he has also served on the board of directors of Inari Agriculture, a company also founded by Flagship Pioneering, which uses its proprietary AI-powered predictive design and multiplex gene editing toolbox to create high performing plant varieties to sustainably improve agriculture.

    "Indigo Ag has ingeniously created solutions to not only maximize the profitability of farming businesses but also to unlock the decarbonization potential of farmland. What Indigo Ag has achieved is a remarkable synthesis that sets it apart — a category of one." said Bekhouche. "It's an intricate combination that others will find incredibly challenging to replicate. I am truly excited to join the Indigo Ag Board at this pivotal juncture. I am looking forward to providing strategic insights and support as Indigo Ag increasingly focuses on profitable growth. The Company's prowess in creating a unique business model positions it as a force with the potential to shape the future of sustainable agriculture."

    Afeyan is founder and CEO of Flagship Pioneering, and a co-founder of Indigo Ag. During his career as inventor, entrepreneur, and CEO, Afeyan has cofounded and helped build over 70 life science and technology companies, including Moderna, and has written numerous scientific publications and is the inventor of over 100 patents.

    Bekhouche and Afeyan will join Berendes, Banks and Hovsepian on the Board of Directors, along with Stéphane Bancel, Andreas Fibig, John Gehring, Geoffrey von Maltzahn, and Deborah Winshel.

    About Indigo Ag

    Indigo Ag is the sustainable agriculture partner that helps farmers and agribusinesses optimize today's yields and profitability, while nourishing the soil for better tomorrows and helping corporations reach their sustainability goals.

    By harnessing science and technology, Indigo Ag's sustainability programs unlock access to high value revenue streams while promoting practices that help land keep its value for future generations. Indigo is currently the only company offering corporations high quality agricultural carbon credits and scope 3 emissions reductions at scale. Our innovative biologicals boost plant growth to help maximize yields, even in tough conditions. And their state-of-the-art digital software facilitates greater efficiency, accuracy and profitability for crop transactions.

    Founded in 2013, Indigo Ag is focused on creating more profitable farmers and more sustainable companies. Operating across 14 countries, the company is delivering on its mission of harnessing nature to help farmers sustainably feed the planet.

    About Flagship Pioneering

    Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. To date, Flagship has deployed over $3.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $26 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics (NASDAQ:DNLI), Foghorn Therapeutics (NASDAQ:FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB) and Tessera Therapeutics.

    Flagship Pioneering Logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dean-banks-appointed-ceo-of-indigo-ag-and-ceo-partner-of-flagship-pioneering-302029919.html

    SOURCE Indigo Ag

    Get the next $DNLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNLI
    $FHTX
    $MCRB
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Foghorn Therapeutics Inc.
    $FHTX
    11/7/2025$12.00Buy
    Guggenheim
    Sana Biotechnology Inc.
    $SANA
    9/24/2025$5.00Outperform
    Wedbush
    Foghorn Therapeutics Inc.
    $FHTX
    9/17/2025$10.00Buy
    B. Riley Securities
    Sana Biotechnology Inc.
    $SANA
    7/3/2025$12.00Overweight
    Morgan Stanley
    Seres Therapeutics Inc.
    $MCRB
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    Denali Therapeutics Inc.
    $DNLI
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    More analyst ratings

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Foghorn Therapeutics with a new price target

    Guggenheim initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    11/7/25 8:30:10 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Sana Biotechnology with a new price target

    Wedbush initiated coverage of Sana Biotechnology with a rating of Outperform and set a new price target of $5.00

    9/24/25 7:58:10 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities resumed coverage on Foghorn Therapeutics with a new price target

    B. Riley Securities resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $10.00

    9/17/25 8:09:57 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:46:20 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    SEC Filings

    View All

    Denali Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Denali Therapeutics Inc. (0001714899) (Filer)

    12/10/25 5:21:33 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Denali Therapeutics Inc.

    424B5 - Denali Therapeutics Inc. (0001714899) (Filer)

    12/10/25 5:20:33 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Denali Therapeutics Inc.

    424B5 - Denali Therapeutics Inc. (0001714899) (Filer)

    12/9/25 4:22:26 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mock James M converted options into 47,190 shares and covered exercise/tax liability with 22,817 shares, increasing direct ownership by 129% to 43,200 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    12/8/25 4:44:18 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 22,817 shares and converted options into 47,190 shares, increasing direct ownership by 84% to 53,231 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    12/8/25 4:40:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Wyrick Susan D. converted options into 20,000 shares and covered exercise/tax liability with 5,132 shares, increasing direct ownership by 11% to 178,263 units (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    12/5/25 5:04:09 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the unde

    12/10/25 12:14:26 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Denali Therapeutics. The proposed offering is subject to market and other conditions, and the

    12/9/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Global AI Infrastructure Shift Ignites Biotech Growth Phase

    Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini 3[1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the shift[2] toward strict rules for AI in medical devices, signaling that the technology is finally ready for real-world commercial use. This rapid move from the lab to the mass market creates a massive opportunity for specialized operators including Aleen Inc. (CSE:ALEN), Moderna, Inc. (NASDAQ:MRNA), GE HealthCare (NASDAQ:GEHC), CeriBell, Inc. (NASDAQ:CBLL), and Palantir Te

    12/9/25 9:25:00 AM ET
    $CBLL
    $GEHC
    $MRNA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical Electronics
    Biotechnology: Biological Products (No Diagnostic Substances)

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

    NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Denali Therapeutics, Inc. (NASDAQ:DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali's lead investigational TransportVehicleTM-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License Application (BLA) for accelerated approval of tividenofusp alfa is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of April 5, 2026. "We are delighted t

    12/4/25 7:10:00 AM ET
    $DNLI
    $RPRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

    SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali's lead investigational TransportVehicle™-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License Application (BLA) for accelerated approval of tividenofusp alfa is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of April 5, 2026. "We are pleased t

    12/4/25 7:00:00 AM ET
    $DNLI
    $RPRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these

    11/5/25 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

    Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on trackDNL126 Phase 1/2 study enrollment completed, supporting an accelerated approval path in MPS IIIATwo new regulatory applications submitted to initiate clinical studies with DNL628 (OTV:MAPT) for Alzheimer's disease and DNL952 (ETV:GAA) for Pompe diseaseTim Van Hauwermeiren, CEO of argenx, to join Denali's Board of DirectorsCarole Ho, M.D., Chief Medical Officer, departing company; Peter Chin, M.D., assuming role of Acting CMO and Head of DevelopmentDenali to host Investor Day on December 4, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 0

    11/6/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Announces Board and Executive Leadership Updates

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali's Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali's Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice President, and President of Lilly Neuroscience. Peter Chin, M.D., is assuming the role of Acting Chief Medical Officer and Head of Development at Denali. Dr. Chin is a neurologist and joined Denali in

    11/6/25 4:00:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

    CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world, will provide up to $3.6 million in additional non-dilutive funding to the Company. The grant will support development and manufacturing of an oral liquid formulation of Seres' Breakthrough Therapy designated SER-155, for medically vulnerable patient populations at risk of bloodstream infections (BSIs), including anti

    10/29/25 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care